Literature DB >> 33615422

The Potentials and Pitfalls of Using Adult Stem Cells in Cancer Treatment.

Mrinal K Das1, Taral R Lunavat2, Hrvoje Miletic2,3, Jubayer A Hossain4,5.   

Abstract

Stem cells play a pivotal role in the developmental stages of an organism and in adulthood as well. Therefore, it is not surprising that stem cells constitute a focus of extensive research. Indeed, several decades of stem cell research have tremendously increased our knowledge on the mechanistic understandings of stem cell biology. Interestingly, revealing the fundamental principles of stem cell biology has also fostered its application for therapeutic purposes. Many of the attributes that the stem cells possess, some of which are unique, allow multifaceted exploitation of stem cells in the treatment of various diseases. Cancer, the leading cause of mortality worldwide, is one of the disease groups that has been benefited by the potentials of therapeutic applications of the stem cells. While the modi operandi of how stem cells contribute to cancer treatment are many-sided, two major principles can be conceived. One mode involves harnessing the regenerative power of the stem cells to promote the generation of blood-forming cells in cancer patients after cytotoxic regimens. A totally different kind of utility of stem cells has been exercised in another mode where the stem cells can potentially deliver a plethora of anti-cancer therapeutics in a tumor-specific manner. While both these approaches can improve the treatment of cancer patients, there exist several issues that warrant further research. This review summarizes the basic principles of the utility of the stem cells in cancer treatment along with the current trends and pinpoints the major obstacles to focus on in the future for further improvement.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer; Extracellular vesicles; Gene therapy; Regenerative medicine; Stem cells; Virotherapy

Year:  2021        PMID: 33615422     DOI: 10.1007/5584_2021_619

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  142 in total

1.  Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors.

Authors:  Irina V Balyasnikova; Melanie S Prasol; Sherise D Ferguson; Yu Han; Atique U Ahmed; Margarita Gutova; Alex L Tobias; Devkumar Mustafi; Esther Rincón; Lingjiao Zhang; Karen S Aboody; Maciej S Lesniak
Journal:  Mol Ther       Date:  2013-09-03       Impact factor: 11.454

2.  Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.

Authors:  Atique U Ahmed; Bart Thaci; Nikita G Alexiades; Yu Han; Shuo Qian; Feifei Liu; Irina V Balyasnikova; Ilya Y Ulasov; Karen S Aboody; Maciej S Lesniak
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

3.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.

Authors:  Lydia Alvarez-Erviti; Yiqi Seow; Haifang Yin; Corinne Betts; Samira Lakhal; Matthew J A Wood
Journal:  Nat Biotechnol       Date:  2011-03-20       Impact factor: 54.908

4.  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas.

Authors:  K S Aboody; A Brown; N G Rainov; K A Bower; S Liu; W Yang; J E Small; U Herrlinger; V Ourednik; P M Black; X O Breakefield; E Y Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor.

Authors:  Gregor B Adams; Karissa T Chabner; Ian R Alley; Douglas P Olson; Zbigniew M Szczepiorkowski; Mark C Poznansky; Claudine H Kos; Martin R Pollak; Edward M Brown; David T Scadden
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

Review 6.  Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission.

Authors:  Frederick R Appelbaum
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

Review 7.  Stem and progenitor cell-mediated tumor selective gene therapy.

Authors:  K S Aboody; J Najbauer; M K Danks
Journal:  Gene Ther       Date:  2008-03-27       Impact factor: 5.250

8.  Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario.

Authors:  Cestmir Altaner; Veronika Altanerova; Marina Cihova; Katarina Ondicova; Boris Rychly; Ladislav Baciak; Boris Mravec
Journal:  Int J Cancer       Date:  2013-09-14       Impact factor: 7.396

9.  Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

Authors:  Ryoko Araki; Masahiro Uda; Yuko Hoki; Misato Sunayama; Miki Nakamura; Shunsuke Ando; Mayumi Sugiura; Hisashi Ideno; Akemi Shimada; Akira Nifuji; Masumi Abe
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

10.  Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow.

Authors:  Mateusz Adamiak; Sylwia Borkowska; Marcin Wysoczynski; Malwina Suszynska; Magda Kucia; Gregg Rokosh; Ahmed Abdel-Latif; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  Oncotarget       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.